I. Abstract
Cystic fibrosis (CF) is an autosomal recessive disorder caused by defective ion transport across various epithelia. Multiple organ systems are affected in this disease; however, the pulmonary complications are the most morbid and life limiting. The primary defect in the lung appears to be abnormal mucociliary clearance. Isolation of the gene responsible for CF in 1989 provided impetus for the development of new therapies based on gene therapy. We propose in this protocol a phase I trial to assess the safety and feasibility of treating CF pulmonary disease by directiy delivering CFTR-expressing, replicationdefective adenoviruses to the airway. The rationale for this human protocol was based on extensive preclinical studies in a variety of animal models including human CF airway xenografts and nonhuman primates.
In this protocol, 20 CF patients will be treated with CFTRexpressing virus and followed for a) evidence of CFTR gene transfer and expression, b) immunological responses to CFTR or adenoviral proteins, and c) toxicity. Adult CF patients with advanced disease who are considered acceptable candidates for bronchoscopy will be considered. A suspension of virus will be delivered to an isolated segment of the lung via a bronchoscope. Pulmonary samples will be harvested for analyses by follow-up bronchoscopies 4 days, 6 weeks, and 3 months following administration of the virus.
II. Background II.A. Cystic Fibrosis
Cystic fibrosis (CF) is the most lethal autosomal recessive disease in the Caucasian population [Boat et al., 1989] . The underlying pathology involves defects in anion transport across various epithelia. Approximately 1 in 2,500 live births are affected by this disease indicating that the carrier frequency is 1 in 25. Cystic fibrosis manifests itself in multiple organ systems including liver (focal biliary cirrhosis), intestines (bowel obstruction), pancreas (malabsorption, pancreatitis, and diabetes), vas deferens (sterility in males) and lung (obstructive pulmonary disease and chronic infections).
Although all mucus secreting organs of the body are affected in cystic fibrosis, it is the pulmonary disease that is responsible for the vast majority of the morbidity and mortality [Wood et al., 1976] . The age at onset of symptoms and the rate of progression of pulmonary disease can vary considerably from patient to patient. However, it is generally accepted that virtually every patient with cystic fibrosis who lives long enough will develop pulmonary complications from their disease. Recent progress in the areas of genetics and cell biology has done much to further our understanding of the pathogenesis of cystic fibrosis. Although a number of significant gaps still exist, the pathogenesis of the pulmonary disease is likely related to the recently described abnormalities in electrolyte transport within the airways. These abnormalities lead to production of an abnormal mucus with altered rheologic properties. This leads to impaired clearance of the bronchial lining fluid with resulting pooling of secretions within the airways. The stagnant secretions are suitable substrates for bacterial growth. For uncertain reasons, staphylococci and pseudomonas species are the most frequently cultured organisms found in the sputum of patients with cystic fibrosis. The repeated episodes of infection cause permanent airway damage of a type that leads to chronic obstruction in airflow and bronchiectasis. Symptomatically, the patient develops cough with sputum production and shortness of breath with exercise. As the disease advances, the level of dyspnea increases until it occurs at rest. With advanced disease, hypoxemia leading to cor pulmonale and right heart failure appear. Eventually ventilatory failure occurs followed by death. Data from 1990 show that the median survival for cystic fibrosis in the United States is 27.6 years.
The treatment of the pulmonary disease in cystic fibrosis has a multifaceted approach. The use of antibiotics is a major component of treatment regimens. Although prolonged eradication of bacteria from the sputum is rarely accomplished, frequent and sometimes prolonged antibiotic therapy helps lower the numbers of bacteria. The development of infection with antibiotic-resistant organisms reduces the effectiveness during later stages of the disease. The antibiotics are administered orally, intravenously, and/or by aerosol.
Bronchodilator therapy has been shown to be effective in subgroups of patients with cystic fibrosis. Studies of the efficacy of 3-agonists [Weintraub and Eschenbacher, 1989] , anticholinergic agents [Weintraub and Eschenbacher, 1989] , and theophylline [Pan et al., 1989 ] demonstrate improved pulmonary function in some patients with the disease. Physical maneuvers to promote secretion clearance such as postural drainage with percussion have long been a mainstay in the treatment of cystic fibrosis. In some patients, secretion clearance can be induced by physical exercise.
When the disease progresses to the point of significant hypoxemia, supplemental inspired oxygen is used in an attempt to delay the onset of cor pulmonale and right heart failure. In the last stages ofthe disease, intratracheal intubation and mechanical ventilation is available. However, the prognosis for successful weaning and extubation is very low and many patients chose to forego the use of mechanical ventilation [Davis, 1978] , Unfortunately, the therapy outiined above is not fully effective. Eventually, the patient's respiratory condition progresses leading to death. New therapies are under development to improve the life span of patients with cystic fibrosis. These include aerosolized amiloride to block excessive sodium reabsorption in the airway and promote hydration of secretions [Knowles et al., 1990] . Topical application of triphosphate nucleotides has been shown to activate chloride secretion from cystic fibrosis epithelium [Knowles et al., 1991] . Aerosolized antiproteases such as secretory leukocyte protease inhibitor [McElvaney, 1991] and a-1-protease inhibitor [Vogelmeier et al., 1991] are being evaluated to see if their use will reduce tissue damage caused by proteases that are released by bacteria and inflammatory cells. Agents such as DNase I are being studied to see if they can promote secretion clearance by reducing the viscosity of the mucus [Hubbard et al., 1992] . Antiinflammatory agents are being evaluated to see if suppression of the assumed excessive immune response will reduce the rate of lung injury [Auerbach et al., 1985; Rosenstein et al., 1991] . Although one or more of these approaches might be efficacious, none of the preliminary studies has shown total reversal of the processes that are known to lead eventually to permanent, severe lung injury.
Lung transplantation has been performed in small numbers of patients with cystic fibrosis [Aitken et al., 1992; deLeval et al., 1991; Frist et al., 1991; Shennib et al., 1992] . This treatment has the potential for correcting the underlying defect in that the transplanted lung appears not to manifest the abnormal electrophysiology characteristic of cystic fibrosis. However, severe limitations of donor organ availability have impeded the performance of large number of transplants. Although mortality rate is improving following transplantation, the two year survival rate still approaches only 50%.
In summary, survival data indicate that the prognosis for patients alive today with cystic fibrosis is much better than 20 years ago. However, the prospect for a normal life span with currently available therapies is not good. A rational approach is to correct the cellular defect at the site where the most serious pathological process occurs, i.e. within the airways. Successful transfection and expression of a normal CFTR gene into airway epithelial cells of patients with cystic fibrosis would correct the underiying abnormality.
The isolation of the gene responsible for CF in 1989 ushered in a new era of research for this deadly disease [Rommens et al., 1989; Riordan etal., 1989; Kerem etal., 1989] . Elegant in vitro studies have begun to unravel the biochemical function of the protein product ofthe CF gene called the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) which appears to be a highly regulated chloride channel [Reviewed in Collins, 1992] . Patients with CF have mutations that render the channel nonresponsive to elevations in intracellular cAMP [Kerem et al., 1989] .
Cloning the CF gene also suggested new strategies for treatment based on gene therapy. In an important first step towards this goal, we reported in 1990 the functional correction of defective chloride transport in a CF cell in vitro by retroviralmediated transfer of a normal CF gene [Drumm et al., 1990] . Translating the advance made in vitro to a practical and effective therapy for CF lung disease was not immediately obvious. Existing experimental paradigms of gene therapy were largely based on transplantation of autologous cells that had been genetically corrected ex vivo with recombinant retroviruses. Safe and effective application of this model to the treatment of CF lung disease seems unlikely. We also considered administration of recombinant retroviruses to the human airway as a way of directiy transferring the therapeutic gene to the appropriate target cell in vivo. We found this to be an extremely inefficient process unless the airway has been injured and the epithelial cells are regenerating [Engelhardt et al., 1992b] . This, in fact, was the predicted result in light of the requirement of cell division for retroviral integration.
The development of effective gene therapies for CF will likely require the creation of new approaches that are capable of targeting genes to airway epithelial cells by direct administration in the airway. Furthermore, gene transfer must be accomplished in a nonreplicating, stable target cell and the recombinant gene should be expressed for a prolonged period of time without pathology. In a series of studies performed in Cotton rats, Crystal and colleagues have provided convincing evidence that recombinant adenoviruses may have the properties described above necessary for safe and effective gene transfer to the human airway [Rosenfeld et al., 1991 and .
Adenoviruses are nonenveloped DNA viruses responsible for many types of self-limited respiratory illnesses in humans. Many serotypes of adenoviruses exist, some of which have been exposed to a large proportion of the population in the United States.
Adenoviruses have been the subject of extensive investigation in the laboratory [Horwitz, 1990] . This has proven to be a powerful system for studying basic mechanisms of gene regulation. The adenovirus exists as a 35 kb double stranded DNA molecule with multiple early and late transcriptional units. The type of recombinant virus proposed in this protocol has been used as a vector system in many in vitro and in vivo settings. The El region is deleted so as to render the virus defective in replication. Under some conditions, such as high multiplicity of infection (MOI), EI deleted viruses can replicate in recipient cells. The recombinant minigene is placed under the control of a heterologous promoter in place of El sequences.
Perricaudet and colleagues have developed El deleted Ad5 for use in vaccines [Levrero et al., 1991] . They have performed experiments in which hepatitis B surface antigen expressing virus was injected into nonhuman primates. Interestingly, no immune response was observed. Of relevance to this protocol was the study by Smith et al. in 1970 in which volunteers were exposed to type 4 adenovirus by inhalation as part of a vaccination trial [Smith et al., 1970] . No substantial morbidity was noted.
II.B. Preclinical Studies

II.B.l. Distribution of CFTR in Human Airway
Design of rational approaches of gene therapy for CF lung disease requires an understanding of the distribution of CFTR expression in the non-CF lung. Extensive experience with the clinical and pathological manifestations of CF suggest that the primary abnormalities in the lung relate to the defects in mucociliary clearance (see section II.A). The prediction, therefore, is that the CF gene is normally expressed in the conducting airway rather than the airspace.
The human airway is a network of branching structures that conduct air from the alveolar sacs where gas exchange occurs to the extemal environment. The general stmcture of the airway varies as it branches from the most proximal site below the larynx (i.e., the trachea) to the most distal terminal bronchioles. Proximal airways are lined with a surface epithelium that is pseudostratified, containing a layer of squamous cells resting on the basal lamina (called basal cells) with a variety of columnar cells including ciliated cells, goblet cells, undifferentiated cells and secretory cells with electron dense granules. Basal and goblet cells are believed to be progenitors that are capable of self-renewal and differentiation into ciliated cells.
Areas of the proximal airway surrounded by cartilage also contain submucosal glands which consist of a network of secretory tubules and associated ducts [Meyrick et al., 1969] . These glands deliver into the airway lumen a complex seromucous secretion essential for mucociliary clearance. The most distal component of the submucosal glands consists primarily of serous tubules and serous acini. The serous cell has exocytotic vesicles that contain a mixture of bactericidal proteins. The mucous tubules, which lie proximal to the serous cells, secrete highly viscous mucous glycoproteins. All serous secretions must pass through the mucous tubules on the way to the airway. Seromucous secretions move from the tubules into collecting ducts which are lined by simple columnar epithelial cells rich in mitochondria. The high mitochondrial content of these cells suggests they may play a metabolically active role in regulating water and ion concentrations in ducts. Seromucous secretions reach the respiratory surface by passing from collecting ducts which, as extensions of the surface mucosa, are lined by a pseudostratified, ciliated epithelium.
The distal airway is normally void of submucosal glands and has a much simpler surface epithelium which is cuboidal in stmcture. There are essentially two types of cells in the distal airway: ciliated cells and clara cells which contain electron dense secretory granules and are believed to be progenitors.
Critical to our understanding of the pathophysiology of CF lung disease is a precise definition of the cellular and subcellular localization of CFTR in the human airway. Previous studies have reported variable success in accomplishing this by direct localization. Immunocytochemical analyses of adult human tissues have successfully localized CFTR in epithelial cells of sweat ducts, small pancreatic ducts, kidney tubules and intestinal crypts, but failed to detect CFTR in the lung [Cohn et al., 1991 and Crawford et al., 1991] . Analysis of RNA extracted from human bronchial bmshings of normal patients indicated that the CF gene is expressed at low levels in the cells released by this procedure, which were primarily ciliated and nonciliated columnar cells of the surface epithelium [Trapnell et al., 1991 ] . In situ hybridization studies of rat trachea show low levels of diffuse staining over the surface epithelium but these studies could make no conclusions about the presence of CFTR mRNA in submucosal glands which are extremely nonabundant in the rodent airway. More recently, Zeitiin et al. detected CFTR protein in primary nasal epithelial cells by Westem blot analysis [Zeitiin et al., 1992] . Function of CFTR has been clearly demonstrated in a variety of cells isolated from the surface epithelium using electrophysiological techniques [Reviewed in Welsh, 1990] .
Techniques of in situ hybridization and immunocytochemistry were used to characterize the distribution of CFTR expression in bronchus from non-CF and CF tissues [Engelhardt et al., 1992b] . The predominant site of CFTR RNA and protein expression in non-CF bronchus was the submucosal glands with the highest expression detected in the ducts and serous tubules although low levels were detected in surface epithelia. Similar analyses performed on bronchi obtained from CF patients demonstrated a distribution of CFTR RNA expression similar to that found in non-CF tissue except there was markedly increased RNA expression in the collecting ducts. Expression of CFTR protein was a function of genotype where the most common mutation, AF 508, is associated with markedly decreased levels of protein in all stmctures, and the less common mutation, G551D allele, is associated with normal distribution of apically localized protein.
Similar techniques were used to localize CFTR in the distal airway. These studies demonstrated high levels of CFTR in a subpopulation of surface epithelial cells (approximately 10-40% of the total) in most noncartilagenous airways (data not shown).
These studies have identified a large number of possible cellular targets for CFTR gene transfer. Functional analysis and localization studies suggest that essentially all of the cells of the proximal surface epithelium and a substantial number of distal airway epithelial cells express CFTR in non-CF tissue and therefore should be targeted in gene therapy. Fortunately, these cell types are easily accessible by inhalation or lavage. CFTR-expressing cells within the submucosal glands will be more difficult to target. The cunent protocol, which is designed to reconstitute CFTR in proximal and distal surface epithelia, is based on the premise that correction of the submucosa is not necessary for some level of efficacy.
II.B.2. Production of Recombinant CFTR Adenovirus
Recombinant adenovimses were generated that express a variety of CFTR alleles. Detailed descriptions of the methods used to constmct the vectors and produce the vimses are provided in Section IV.
The recombinant vims used in this protocol, Ad.CB-CFTR, is based on AdS. In this vector, sequences spanning the El region from 1 to 9.2 mu are deleted and replaced with a minigene containing CMV enhancer, P-actin promoter, CFTR cDNA, and SV40 late gene polyadenylation site. The recombinant vims is also deleted of E3 sequences.
H.B.3. Complementation ofthe CF Defect In Vitro
The function of Ad.CB-CFTR was evaluated in the cell line CFPAC which was derived from the pancreatic adenocarcinoma of a CF patient. Infectivity of the cell line with recombinant AdS was determined initially with lacZ adenovims and subsequentiy with Ad.CB-CFTR. CFPAC populations exposed to adenovims at an MOI of I demonstrated expression in 30-40% of the cells. Recombinant CFTR protein expression was detected by immunocytochemistry in 100% of the cells after exposure to Ad.CB-CFTR at an MOI-SOO. The function of adenoviral-transduced CFTR protein was assessed by measuring cAMP mediated stimulation of Cl conductance using the halide sensitive fluorophone SPQ. In this assay, halide efflux is measured by an increase in fluorescence in cells loaded with SPQ and iodide. Substitution of NO3 with iodide in the medium of each population of cells produced littie change in fluorescence. Subsequent increase in the intracellular cAMP by the addition of forskolin and IBMX stimulated a rapid rise in 100% of the cells infected the wild type Ad.CB-CFTR vims which was quenched when iodide was substituted for NO3. None of the cells that were mock infected demonstrated cAMP mediated changes in fluorescence. Cells infected with Ad.CB-CFTR at MOI's ranging from 50 to 500 consistentiy produced good SPQ responses in 100% ofthe cells.
Experiments were performed to test the feasibility of detecting recombinant derived CFTR in primary isolates of CF airway epithelial cells. Cells removed from the main stem bronchus of a CF patient were plated in culture and exposed to either Ad.CMV-lacZ or Ad.CB-CFTR at an MOI of 500. High levels of recombinant derived CFTR were clearly detected in 100% of the Ad.CB-CFTR cells. Techniques are being developed for measuring cAMP mediated Cl conductance in the primary cultures using the SPQ assay.
II.B.4. Xenograft Model of the Human CF Airway
A critical evaluation of the safety and efficacy of adenoviralmediated transfer of the CFTR gene to human airway would be greatiy simplified if there was an authentic animal model. Critical questions relate to the biology of EI deleted AdS in the context of a human airway and parameters necessary to achieve functional correction in this stmcture. Most curtentiy available animal models fall far short. A major problem is that the airway of humans differs substantially in function and anatomy from that of other species. For example, many species, including rodents, are essentially void of the sites of mucous production found in humans (i.e., goblet cells of the surface epithelium and submucosal glands). This may explain why the recentiy described murine models of CF, generated by mutating CFTR in the germ line, have no pathology in the lung [Snouwaert et al., 1992] . Another important consideration is the marked variation in infection and replication of adenovims that is observed in recipient cells from different species.
Our strategy was to develop a model based on the development of a CF human airway xenograft established in a nu/nu mouse [Engelhardt et al., 1991 ] . Primary airway epithelial cells are released from lung tissue obtained in the setting of lung transplantation. CF cells are obtained from the bronchi of diseased lung that has been removed, and non-CF cells are ob-tained from proximal airway of the lung that is being transplanted into the CF patient. The cells are cultured for several days in the presence of antibiotics, released with trypsin, and seeded into the lumen of rat trachea that have been stripped of their epithelium by freeze thawing. The seeded grafts are then implanted subcutaneously into the flanks of nu/nu mice with the proximal and distal ports of the graft open to the environment via tubing ligated to the ends. The grafts are inigated with normal saline biweekly to remove accumulations of mucus.
The grafts are allowed to mature in vivo for 3 weeks after which a fully differentiated pseudostratified epithelium has developed. We have now generated 108 grafts from 18 non-CF bronchial samples and 104 grafts from 13 CF bronchial samples.
The xenografts have been subjected to extensive morphometric analysis in order to evaluate the suitability of the model. Blocks of tissue from a non-CF and CF xenograft were carefully examined by transmission electron microscopy. Overall stmcture ofthe epithelium, distribution of cell types (i.e., ciliated, goblet, basal, and undifferentiated), and ultrastmctural features of the various types of cells were determined. These findings were compared to similar analyses of native main stem bronchus (non-CF and CF) located adjacent to the area from which the cells destined for xenografts were removed. There were no obvious differences in the overall stmcture or ultrastmctural features of the various samples except that the native stmcture occasionally appej^ed taller. The distribution of cell types did not significantly differ between the non-CF bronchus and non-CF xenograft or the non-CF and CF xenograft. The CF bronchus had a significantly increased distribution of goblet cells when compared to the CF xenograft suggesting environmental stimuli may be responsible, in part, for goblet cell hyperplasia in CF (32% in bronchus vs. 24% in graft). A detailed description of the electrophysiologic properties of the non-CF and CF xenografts are presented in section II.B.6.
II.B.5. Safety and Efficacy Studies in Human Non-CF Xenografts
Introduction. Xenografts generated from non-CF cells were used to address several issues critical to the evaluation of the feasibility and safety of adenoviral-mediated gene transfer to the human airway.
Xenografts repopulated with a fully differentiated epithelium were infected with purified stocks of a recombinant vims expressing the easily detectable marker gene lacZ [Engelhardt et al., 1993b] . This vims was selected because the product of lacZ is easily detected in situ and the overall stmcture of the vims is similar to the Ad.CB-CFTR vims. This recombinant called Ad.RSVlacZ has a lacZ minigene expressed from a RSV promoter in place of El sequences as well as deletion of the E3 region. Into the lumen ofthe grafts were injected the following vimses: 1) Ad.RSVlacZ, 2) El deleted adenovims (AdEldelta), 3) wild type AdS, and 4) PBS ("mock"). The vims was expelled and the xenografts were subjected to the analyses. Specific details of the experiments are provided below.
Efficiency and persistence of adenoviral-mediated gene transfer in human bronchial epithelium. Xenografts were infected with concentrated purified stocks of Ad.RSVlacZ adenovims at 10'^ pfu/ml, 10^ pfu/ml, and 10* pfu/ml for a total of 1 hour. The El deleted adenovims (AdEldelta) at 10'^ pfu/ml was used as a negative control. The grafts were harvested, fixed, stained in X-gal and visualized enface through a dissecting microscope in order to assess the overall efficiency of infection. Xenografts infected with the AdEl delta demonstrated no X-gal positive cells when harvested 3 days after exposure to vims, while large areas of lacZ expression were demonstrated in grafts exposed to Ad.RSVlacZ at 10'^ pfu/ml and harvested at day 3. Morphometric analysis of GMA sections of this xenograft indicated gene transfer in 11% of the epithelial cells. Xenografts infected with Ad.RSVlacZ at 10' and 10* pfu/ml demonstrated gene expression in 1.9% and <0.I% ofthe total cells of the epithelium, respectively, when harvested at three days.
To analyze the stability of adenoviral lacZ expression within the bronchial epithelium, xenografts were also harvested 21 days following infection with 10' pfu/ml Ad.RSVlacZ adenovims. No changes in the percentage of X-gal positive cells were seen between 3 days and 21 days postinfection.
Similar experiments were performed with Ad.CB-CFTR vims to assess the efficiency of recombinant CFTR expression in the xenografts. Non-CF xenografts were exposed to 10'° pfu/ml of vims and subsequentiy explanted, frozen, cryosectioned, fixed and immunostained using the CFTR COOH terminal antibody. Grafts exposed to the lacZ vims demonstrated autofluorescence below the basal laminal and low level fluorescence in basal cells representing endogenous CFTR expression. The grafts exposed to Ad.CB-CFTR demonstrated very high level of CFTR expression in approximately 2-10% ofthe cells. Both ciliated and secretory cells expressed the recombinant CFTR which in each case was localized on the apical basal lamina. Recombinant CFTR was also expressed in a number of intermediates cells. All types of surface epithelial cells expressed the recombinant CFTR. These experiments indicate that high levels of recombinant CFTR expression can be achieved in the surface epithelium. Furthermore, the recombinant protein is appropriately localized to the apical plasma membrane.
Efficiency of infection ofthe various bronchial epithelial cell types. Quantification ofthe various cell types infected by 10'^ pfu/ml adenovims was performed by analysis of 1,000 transgene-expressing cells detected by X-gal staining and [S-galactosidase immunocytochemistry. With a total of 11.1% lacZ positive cells in the epithelium, 5.5% were ciliated cells, 0.3% were basal cells, 3.8% were goblet cells and 1.5% were intermediate cells. The diffusion of X-gal precipitate and the apparent non-nuclear localization of a majority of the expressing cells made the quantification of cell types within these large, highly expressing clusters difficult. We performed quantitation of lacZ positive cells by immunocytochemistry using a [3-galactosidase polyclonal antibody as confirmation of these results. In contrast to X-gal staining, which frequentiy produced a reaction product distributed throughout the cytoplasm, all positive cells detected by antibody staining showed a clear concentration of staining within the nucleus. The ability to detect p-galactosidase by immunofluorescence provided the opportunity to co-localize recombinant gene expression in either basal cells (cytokeratin 14) or columnar cell (cytokeratin 18) markers. Of 1,500 lacZ positive cells counted only 1 colocalized with the basal cell marker.
Expression of adenoviral proteins within human bronchial epithelium. Adenoviral protein expression from both wild type and recombinant adenovims was analyzed by immunocytochemical techniques. Antibodies generated to purified adenovims hexon protein (1056F) and purified adenovims type 3 fiber protein (805F) have been shown to crossreact with all 43 human adenoviral serotypes. Both antibodies were directly labeled with FITC and used in double immunofluorescence studies with the polyclonal P-galactosidase antibody. Wild type adenoviral infection into xenografts produced immunoreactive cells with both adenoviral antibodies 805F and 10S6F (data not shown) at 21 hours postinfection. In contrast, retrovirally infected grafts showed no reactivity with these antibodies. Xenografts infected with 10'^ pfu/ml recombinant Ad.RSVlacZ adenovims showed no evidence of adenoviral protein expression within 1,500 lacZ positive cells analyzed.
Recovery of adenovirus from xenografts. Xenografts infected with Ad.RSVlacZ were inigated with PBS approximately every third day and the inigants layered on 293 cells and evaluated for vims using the pfu assay. There is a progressive decrease in the quantity of vims recovered during a 2 week period following the initial infection; no vims was detected beyond 14 days.
Summary. These experiments address several critically important issues relevant to gene therapy of CF with El deleted adenovirus. First, they demonstrate potentially therapeutic levels of gene transfer over a log range with respect to the dose of recombinant vims. In addition the experiments indicate that the adenoviral gene persists and the recombinant minigene is stably expressed for at least 3 weeks without apparent diminution. This model would not detect loss of adenoviral infected cells due to a destmctive immune response because the xenografts are maintained in an immune deficient animal.
This model also provides an excellent opportunity to address two important questions: Do the transducted cells express viral stractural genes? Does the genetically reconstituted graft produce and shed viras? In each case the answer appears to be no. This suggests that replication of El and E3 deleted Adenoviras type 5 recombinants will not occur in a human airway. The xenograft is a very sensitive model of replication because the production and propagation of viras would not be blunted by an immune response, which would be present in patients but absent in the nu/nu mouse.
II.B.6. Complementation in Human CF Xenografts
In order to assess the feasibility of gene therapy it is important to determine the level of genetic reconstitution that is necessary for detectable improvement in the electrophysiological properties of the human airway. Furthermore, it is important to determine if this level of conection is possible with the vims under consideration for human trials (Ad.CB-CFTR). This issue was initially addressed by Johnson et al. in which they studied in the bioelectric properties of epithelial sheets formed in vitro with mixtures of CFTR negative and CFTR positive cells [Johnson et al., 1992] . Their data indicate that as few as 6-10% genetically conected cells within an epithelial sheet generated Cl transcript properties similar to sheets comprised of 100% conected cells.
We studied this question in CF xenografts exposed to Ad.CB-CFTR vims. CF grafts were exposed to either Ad.CMV-lacZ or Ad.CB-CFTR and subsequently evaluated in situ for conection of cAMP transport across the epithelium using a modification of the procedure described by Johnson et al. Nu/nu mice that carried xenografts were anesthetized with ketamine/xylazine in preparation for in situ functional assays. The basic concept is to measure transepithelial potential difference (PD) in response to various stimuli. The ground electrode is placed subcutaneously and the measuring electrode is placed in the graft lumen bathed in the indicated solution. The initial measurement is made in the presence of 120 mM Cl. The luminal bath was subsequently changed in the following way: a) amiloride is added, b) Cl is decreased from 120 to 3 mM, and c) forskolin is added.
Introduction of the Na channel blocker amiloride to the lumen bath leads to a drop in PD (i.e., less negative) in both non-CF and CF grafts. The PD increases (i.e., becomes more negative) in a stepwise manner in the non-CF graft when luminal Cl is decreased (representing basal conductance through CFTR) and when CFTR is stimulated with forskolin.
CF xenografts exposed to Ad.CMV-lacZ or Ad.CB-CFTR were subjected to similar studies. The CF graft exposed to Ad.CMV-lacZ was indistinguishable from the noninfected CF graft while the CF graft exposed to CFTR adenovims demonstrated significant increases in PD in response to changes in luminal Cl and forskolin.
These xenografts have been explanted and evaluated for efficiency of genetically reconstituted cells. Previous experience indicates that CFTR expression should be detected in 5-20% of the cells. Analyses of these grafts are underway.
These results indicate that single exposure of a CF epithelium to Ad.CB-CFTR results in detectable differences in the bioelectric properties consistent with partial conection of CFTR function.
II.B.7. Safety Studies in Transgenic Mice
Important safety concems of this protocol relate to the consequences of ectopic and/or unregulated CFTR expression in the human lung. For example, will there be deleterious effects of CFTR expression in cells of the lung that do not normally express this gene? In collaboration with Dr. Jeff Whitsett, at the University of Cincinnati Medical Center, we established transgenic mouse lines that express human CFTR under the control of transcriptional elements derived from the human surfactant protein C(SP-C) gene [Whhsett et al., 1992] .
The hCFTR mRNA was expressed in lungs and testes: in the lung, we found hCFTR mRNA in bronchiolar and alveolar epithelial cells and CFTR protein in respiratory and epithelial cells. While the level of expression of hCFTR mRNA varied, hCFTR mRNA and protein were detected in pulmonary epithelial cells of several lines at high levels. Lung weight, morphology, somatic growth and reproductive capacity were not altered by expression hCPTR in lung and testes of the transgenics. Our findings suggest ectopic and unregulated expression of human CFTR in lung epithelial cells may not be deleterious.
II.B.8. Safety and Feasibility Studies in Nonhuman Primates
Experiments were performed in three Rhesus monkeys (Macaca mulatta) to further assess the feasibility and safety of gene therapy using El deleted adenovimses. Each animal was anesthetized, intubated, and ~3 ml of purified virus was administered into the airway through the endotracheal tube while the animal was lying in the left lateral decubitus position. Two animals (9037 and 9650) received Ad.CMV-lacZ and one animal (8829) received Ad.CB-CFTR. The animals were monitored clinically and serial blood hematology/chemistry were evaluated. Animals 9037 and 8829 were necropsied 3 days after administration of vims; animal 9650 will be necropsied 3 weeks post-infusion. A summary of the experiment is presented in the 3 X 10" 3 X 10" 3 X 10"
found predominantiy within the segments of lung targeted for gene delivery. Gene expression was most pronounced within alveolar cells. The intensity of staining was proportional to the dose of vims delivered and was found to diminish over time. The proximal and distal airways also showed transgene expression, but only in scattered patches. Immunostaining for virally encoded proteins showed occasional expression of an E2A gene product (i.e. DNA-binding protein) and no evidence of viral capsid protein (i.e. fiber protein).
Clinically, the animals did well without behavioral changes or weight loss. Blood counts, semm electrolytes, liver function tests, and renal function tests did not appear to be altered by the vims. However, pulmonary alveolar inflammation was seen in a dose dependent manner, predominantly in the areas of lung that were most intensively exposed to the vimses. The inflammatory infiltrate consisted mainly of lymphocytes and macrophages with neutrophils and eosinophils making up a very minor proportion of the cells. At its highest intensity, there was diffuse alveolar wall damage with intra-alveolar edema. Only in the animals receiving the highest dose of vims (7.0 x 10'° pfu) was the inflammation observable by chest radiograph. Over time, the infiltrates resolved.
III. Experimental Design
The animals tolerated the procedure well without obvious clinical sequalae. Necropsy evaluations of animals 9037 and 8829 three days after administration of vims failed to reveal pathology. Blood chemistry and hematology values remained within normal limits.
We have begun characterizing tissues from 9037 for evidence of adenovims mediated gene transfer. Tissues from various organs were frozen, cryosectioned, mounted, and stained in X-gal. No staining was detected above background in brain, liver, spleen, kidney, heart, and testes. Significant staining was seen throughout the lung. There was patchy staining in proximal airway covering 1-2% of the surface and a majority of staining in the air space (alveolar cells and macrophages) with some reaction noted in distal airways.
A large scale evaluation of the safety and efficacy of adenoviral mediated gene transfer was performed using baboons [Engelhardt et al., 1993a; Simon et al., 1993] . The experimental design was constmcted to simulate the human clinical trial which uses Ad.CBCFTR. Twelve animals were used in the study in which Ad.CMWacZ and Ad.CBCFTR were instilled into separate segmental bronchi using a bronchoscope. During and for 10 minutes following instillations of the vims, the bronchoscope was held gently wedged in the orifice of the bronchus in an effort to restrict the vims to the intended lung segment. The animals, each weighing approximately 12 kg, were divided into 4 groups with each group receiving a different titer of vims (7.0 x 10^ 7.0 x 10*, 7.0 x 10', and 7.0 x 10'" pfu). One animal from each group was sacrificed 4 days after gene administration, 1 animal after 21 days, and I animal has been kept as a long term survivor. The long term animals have undergone repeat bronchoscopies on days 4 and 21.
Using immunohistochemical staining for CFTR and cytochemical staining for P-gal activity, transgene expression was
III.A. Patient Selection
A total of 20 patients with cystic fibrosis will be recmited from areas sunounding Ann Arbor, MI and Philadelphia, PA by contacting in person, by telephone, and by letter: 1) CF Center Directors, and 2) Physicians specializing in pulmonary medicine or other specialties who are known to be active in providing care for patients with cystic fibrosis. The list of physicians will be obtained from CF Center Directors.
Entry into the study will be contingent upon fulfilling the following criteria: Inclusion Criteria 1. Proven diagnosis of cystic fibrosis. Proof will consist of documentation of both: a) Sweat sodium or chloride > 60 mEq/1 by the pilocarpine iontophoresis method or cystic fibrosis genotype b) Clinical manifestations of cystic fibrosis. 2. Age: s=18 years old. 3. Gender: Males or females. 4. Severity of disease: To be eligible, a patient must be in adequate clinical condition to safely undergo the planned procedures, i.e., bronchoscopies. An acceptable reserve will be defined as having a clinical condition such that the estimated 2 year survival is >50%. Using the study of Kerem et al. [Kerem, 1992] , patients will be considered to have a greater than 50% chance of two years survival if they fulfill all of the following: a) FEV, 3= 30% predicted b) PaOj > 55 mmHg while breathing room air c) PaCOj < 50 mmHg while breathing room air Although the disease severity criteria have been selected to avoid entering patients with near terminal pulmonary disease, the intent nevertheless is to study those with at least moderate to severe lung disease and a substantially shortened predicted survival. To select only those with an estimated chance of 5 year survival of ^50%, the patient must fulfill the following criterion [Huang, 1987; Shwachman, 1958] : d) Shwachman-Kulczycki clinical score ^50. Exclusion Criteria 1. Conditions which would place the patient at increased risk for complications from participating in the study would include: a) Pneumothorax within the last 12 months b) Insulin-dependent diabetes c) Asthma or allergic bronchopulmonary aspergillosis requiring glucocorticoid therapy within the last two months d) Sputum culture growing a pathogen which does not have in vitro sensitivity to at least two types of antibiotics which could be administered to the patient. e) History of major hemoptysis: Coughing up greater than 250 ml of blood within a 24 hour period during the last year. f) Any medical condition or laboratory abnormality which, according to the opinion ofthe investigators, would place the patient at increased risk for complications. 2. The patient will be carefully evaluated for evidence of active adenoviral infection. History and physical examination will be used to identify clinical evidence for adenoviral syndromes such as coryza, pharyngitis, tonsillitis, bronchitis, pneumonia, conjunctivitis or dianhea. A variety of specimens will be evaluated for adenovimses using culture techniques as well as immunofluorescent and enzyme-linked immunosorbent assays performed directly on the specimen. Evidence for active adenoviral infection at the time of therapy will be a basis for exclusion. Another relevant question relates to previous exposure of the gene therapy recipient to AdS and similar serotypes based on adenoviras specific neutralizing antibodies. We expect that virtually all of our adult patients will have been exposed to adenovirases that confer humoral immunity to AdS. This is based on a large body of literature which indicates that the lower numbered adenovimses Adl, Ad2, AdS, and Ad6 are endemic in most countries. The prevalence of adenovims-specific neutralizing antibodies by the age 3 is estimated to 80% in the USA (Hueber et al., 1954; Sterner, 1962; Hall et al., 1971; Foy and Grayston, 1976) . All patients enrolled in the protocol will be evaluated for previous exposure to AdS and related types using a variety of serologic assays. We expect that essentially every candidate patient will be seropositive. In fact any patient that is not seropositive will be excluded from the protocol. Existing humoral immunity to the viras is considered a safety feature thereby preventing dissemination beyond the localized area of lung to which the recombinant is exposed. 3. Drag therapy: Treatment with systemic glucocorticoids within two months prior to initiation of the study. 4. Inability to comply with the protocol. Patients will be excluded if, in the opinion of the investigators, they have characteristics which would make compliance with the protocol unlikely, e.g. drag abuse, alcoholism, psychiatric instability, inadequate motivation. S. Participation in another investigational therapeutic study within the previous 90 days.
III.B. Patient Evaluation
The following evaluations will be performed at various times throughout the study:
1. History and physical examination A history relevant to the manifestations of both cystic fibrosis and unrelated diseases will be taken. A full review of systems, medication usage, and drag allergy history will be obtained. Patients will be allowed nothing by mouth for 6 hours prior to the procedure. They will be premedicated with 0.2 mg glycopynolate and SO mg meperidine intravenously 30 minutes before bronchoscopy. Electrocardiogram, pulse rate, and pulse oximetry will be continuously monitored. Blood pressure will be monitored every 5 minutes by an automated noninvasive system. Viscous lidocaine 2% (30 ml) will be gargled and expectorated. Lidocaine 4% will be sprayed onto the posterior pharynx and larynx by a hand held atomizer. The bronchoscope will be introduced through the nose in patents without nasal obstmction or evidence of polyps. If the nasal approach cannot be used, the bronchoscope will be introduced orally. In patients undergoing bronchoscopy by the nasal route, oxymetazoline hydrochloride 0.05% will be applied topically to the mucosa of one nasal passage with a cotton swab. Lidocaine jelly 2% will be instilled into the same nasal passage. Supplemental oxygen by cannula will be administered at the mouth at 6 liters/minute. Midazolam will be administered intravenously in 1-2 mg boluses over 15 seconds every 5 minutes until the patient is relaxed but still arousable by verbal stimuli. Additional midazolam will be administered in 1 mg boluses up to every 15 minutes to maintain this level of sedation. A flexible fiberoptic bronchoscope will be introduced transnasally. Lidocaine 2% will be injected through the bronchoscope to anesthetize the larynx and airways as needed. 11. Bronchoalveolar lavage 50 ml aliquots of normal saline will be injected through the bronchoscope that has been gently wedged into a segmental bronchus. The lavagate will be aspirated into a suction trap. The procedure will be repeated until three aliquots have been administered and recovered. 12. Mucosal epithelial cell bmshing: A sleeved catheter with intemal bmsh will be introduced into the bronchus [Kelsen, 1992] . The bmsh will be mbbed against the epithelial mucosa and the adherent cells removed by agitating the brash in sterile medium.
III.C. Clinical Protocol
Screening evaluation. Evaluation must be performed within four weeks of gene therapy. Written informed consent will be obtained prior to participation in the screening evaluation.
Information obtained during screening will be: History and physical exam Clinical laboratory blood tests Pulmonary function tests Pulse oximetry and arterial blood gas Electrocardiography (12-lead) PA and lateral chest x-ray Thin-cut CT scan Sputum culture with antibiotic sensitivities Shwachman-Kulczycki Score calculation
Pretransfection treatment
Beginning 2 weeks prior to transfection, the patient will begin an intensified treatment protocol to reduce respiratory infection and maximize overall condition. For the two weeks, the patient will receive two anti-Pseudomonal antibiotics to which his/her cultured organism is sensitive. Twice a day postural drainage and percussion will be performed. The patient will continue on the remainder of his/her chronic treatment regimen. This phase can be accomplished either as an inpatient or outpatient. During the subsequent studies, the patient will continue on their previously prescribed medical program. This includes continuation of any oral antibiotics, pancreatic enzymes, theophylline, and vitamin supplements. Aerosilzed bronchodilators and antibiotics will be continued.
Selection of segment for transfection
The chest x-ray and thin cut CT scan will be used to select an anatomical pulmonary segment that: a) Has a degree of disease involvement average for that patient b) Is in a location such that the patient can be positioned at bronchoscopy so that the segmental bronchus is gravitationally dependent
Transfection procedure
The patient will be prepared for bronchoscopy as indicated above. The bronchoscope will be introduced and advanced to the orifice of the segment chosen for the transfection. Secretions present within the segmental bronchus will be aspirated through the bronchoscope. The bronchoscope will be gently wedged into the target segmental bronchi and 7 ml of normal saline will be installed as a control condition. The fluid will be trapped within the pulmonary segment for 10 minutes by keeping the bronchoscope wedged for that period of time. Next, another pulmonary segment which is the minor image of the segment that received the control solution will be treated with Ad.CBCFTR contained in normal saline. The patient will be kept supine for an additional 30 minutes to minimize further spread of the instilled solution. The study uses a dose escalation protocol with successive pairs of patients receiving progressively higher concentrations of vims. In particular, the first 2 patients will each receive a one-time administration of 7.0 X 10^ pfu (total). Subsequent pairs of patients will receive 2.1 X IO**, 7.0 X 10", 2.1 X 10^ 7.0 x 10\ 2.1 x 10*, 7.0 x 10*, 2.1 X 10", 7.0 x 10', and 2.1 x 10'° pfu. There will be a minimum of 3 weeks between patients to allow for adverse effects to be manifested, should they occur.
Post bronchoscopy monitoring
Vital signs including blood pressure, pulse, temperature, and respiratory rate will be measured and recorded every five minutes for the first hour, every IS minutes for the next two hours, every one hour for the next six hours, and every two hours for the next IS hours, and every four hours for the rest of the week post-transfection. Continuous electrocardiographic and pulse oximetry will be measured for the first 24 hours. The clinical laboratory blood tests that are listed above, pulse oximetry, and PA and lateral chest x-rays will be performed daily for the first week, twice a week for the second week, and weekly thereafter for six weeks. Thin cut CT scans will be performed on the day prior to the follow-up bronchoscopy. Following the administration of viras the patients will be kept in an isolation room with full respiratory precautions. This involves a negative pressure room in which the air is filtered and delivered outside. Anyone entering the room will wear a gown, mask, eye protection, and gloves. The patient will be in isolation for at least 7 days after initiation of therapy. While in the hospital the patient will have his/her sputum, nasal swab, urine and stool analyzed for replication competent adenovimses of any serotype using standard adenovims assays. These samples will also be evaluated for CFTR recombinant vims using the PCR assay described in sections IV.D.2.e. Isolation will be discontinued after 3 consecutive daily tests for recombinant advenoviras are negative by RT-PCR. In the unlikely event that the patient continues to shed recombinant CFTR adenovims in the airway, he/she will be kept in the hospital for a longer period of time. 
III.D. Evaluation of Therapy
The patient will be carefully monitored for toxicity, immunological response to CFTR protein or adenoviral proteins and efficiency and stability of gene transfer.
1. Toxicity-Serial examinations to include PFT's, blood chemistry, hematology and cultures for adenovims will be performed. Bronchoalveolar lavage fluid obtained during each follow-up bronchoscopy will be carefully analyzed for wild type and recombinant viras.
Immunological responses-A major aspect of this protocol
is to evaluate the serological response to the patient. The patient's semm and bronchoalveolar lavage fluid will be evaluated for serological responses to wild type CFTR and adenoviral proteins. 3. Efficiency and stability of gene transfer-Bronchoscopy performed following gene transfer will provide an opportunity to assess gene transfer and CFTR expression. Superficial airway epithelial cells will be harvested by bmshing and plated in culture. These cells will be analyzed for CFTR protein and adenoviral protein expression using techniques of immunocytochemistry (see sections II.B.l and II.B.3). Functional conection will be assessed in cultured cells using the functional assay described in section II.B,3.
IV. Isolation and Production of CFTR Adenoviruses
IV.A. Vector Construction
Step 1. Constmction of pAdBglll. The purpose of this step was to construct a plasmid containing the 5' portion of Ad 5 with deletion of El sequences and a unique cloning site. The plasmid pEHX-L3 contains sequences from AdS spanning map units 1 to 16.1. pEHX-L3 was digested with EcoRI and Bglll and a 5.2 kb fragment isolated, which contains the adenoviral sequences from map units 9.2-16.1 and the plasmid backbone (derived from pAT and described in Falck-Pedersen et al., 1989) . The adenoviral sequences from map unit 0-1 which contains the 5' inverted terminal repeat, origin of replication and encapsidation signal were amplified from the original pEHX-L3 using PCR to insert a Nhe I site immediately downstream of the EcoRI site, and a Bglll site at the 3' end. This PCR fragment and the EcoRFBglll 5.2 kb fragment were ligated to produce the plasmid pAdBglll.
Step 2. Constmction of pAd.CMV-lacZ. A complete minigene containing the CMV enhancer and promoter, the lacZ gene, and the SV40 late gene polyadenylation signal was cloned into the Bglll site of AdBglll. The source of the minigene cassette was plasmid pCMV-p (provided by Grant MacGregor, Baylor). A description and schematic of the constmction of pCMV-p have been provided by Dr. McGregor. The description is presented below verbatim.
pUC19 (Yanisch-Penon et al., 1985) was used as abackbone for the constmction of pCMV-p. An 8mer Notl linker (New England Biolabs #1029) was cloned into the Smal site of pUC19. This destroys the Smal site, but generates in the process two Sacll sites, one immediately on each side ofthe Notl linker. This vector was designated pN. To provide a polyadenylation signal, a 196 bp fragment from the SV40 genome (nucleotides 2533-2729) was purified from an SV40 containing vector and, following the addition of BamHI linkers, this fragment was cloned into the unique BamHI site within pN. The fragment is oriented such that RNA polymerase transcribing from a promoter upstream of the Noti site passing through the Notl site and into the SV40 fragment will encounter the SV40 late gene polyadenylation signal (the early gene polyadenylation signal appears in the opposite orientation). This vector was designated pNA. A 180 bp region ofthe SV40 genome containing late viral protein gene 16s/19s splice donor and accept signals [obtained as a Xhol-Pstl fragment from pLl (Okayama and Berg, 1983)] was cloned into pNA to provide the appropriate signals. This vector was designated pNAss. The human cytomegalovims immediate early gene promoter and enhancer was obtained as a 619 bp Thai fragment from pCMS029 (Boshart et al., I98S) . This was cloned into the Hindi site of pUC18 and subsequently recovered as a BamHI/Hindlll fragment which was treated with T4 DNA polymerase prior to blunt end ligation into the vector pNAss. The E. coli P-galactosidase gene from pC4AUG (McGregor et al., 1987) was excised as a 3S30bp EcoRI-Xbal fragment and, following the addition of Notl linkers, cloned into the unique Notl site of the vector.
The entire minigene containing the CMV promoter, lacZ gene, and SV40 polyA were excised from pCMV-P on an SphI fragment. This fragment was treated with Klenow and ligated with Bell linkers. The pAdBglll vector was digested with Bglll and treated with calf intestinal phosphatase before the Bell linkered minigene was cloned in direct orientation into the Bglll siteofpAdBglll.
Step 3. Constmction of pAd.CMV-lacZ. The purpose of this constraction was to remove the CMV promoter and lacZ gene from the pAdCMV-lacZ vector and introduce a fragment containing a portion of the CMV enhancer, the chicken P-actin promoter, the full-length CPTR minigene and a small portion of retroviral sequences from Mo-MLV. A brief description ofthe retroviral vector from which the CFTR gene was described is provided below.
The backbone structure of this vector called pBA-CFTR includes an intact S'LTR of Moloney murine leukemia viras (Mo-MLV) with additional Mo-MLV sequences between the 5' LTR and the internal promoter spanning nucleotide 146 at the border of US to the natural Xhol site in the gag coding region at nucleotide 624 (see Van Beveren et al., 1985) . The plasmid also contains wild-type Mo-MLV sequences from the Clal site at nucleotide 7674 (which was converted to a BamHI site with synthetic linkers) to the end ofthe 3' LTR. Sequences containing the viral enhancer elements of the 3' LTR from the Pvull site at nucleotide 7933 to the Xbal site at nucleotide 8111 have been deleted. In addition to these sequences, there are flanking mouse genomic DNA and pBR322 sequences (spanning the Hindlll site to the EcoRI site). The initial promoter used in this vector was derived from a Xhol to Mbol fragment of the chicken P-actin gene spanning nucleotides -266 to -I-1 (Kost et al., 1983) . The Mbol site was converted to a BamHI site and the modified P-actin fragment was cloned into the parent vector, called pgagBA. The human CFTR coding sequences were derived from a 4.6 kb Sad fragment which contains the complete coding sequence and small 5' and 3' untranslated regions (Riordan et al., 1989) . The Sad sites were converted to Bell sites and the modified fragment was cloned into the BamHI site of pgagBA. This vector is called pgagBA-CFTR. An enhancer was introduced into the Xhol-site of this vector. These sequences were derived from an area 5' to the immediate early (IE) gene ofhuman cytomegaloviras [from Spel (at -580 of IE gene) to Pstl (site in vector sequence) of CDMI, Seed et al., 1987] were subcloned into PUC19. A portion containing IE enhancer sequences was removed on a Xhol (from polylinker) to Ncol (-220 of the IE gene) fragment (for numbering of IE enhancer see Boshart et al., 1985) . Synthetic linkers were used to convert the Ncol site to a Xhol site and the modified fragment was cloned into the unique Xhol site of pgagBACFTR located 5' to the P-actin promoter. This new vector is called pCMV-B A-CFTR.
The retroviral vector pCMV-BA-CFTR was digested with Xhol and Nhel to release a fragment (BA-CFTR) containing the chick p-actin promoter, the 4.6 kb human CFTR cDNA and a small portion of retroviras-specific sequences. The plasmid pAd.CMV-lacZ was cut with SnaBl and Notl to remove CMV promoter and lacZ stmctural gene, and the plasmid backbone retaining the CMV enhancer and the SV40 polyadenylation signal was blunted and ligated with the blunted BA-CFTR fragment to form the plasmid pAd.CB-CFTR.
IV.B. Generation of Recombinant
Ad.CB-CFTR Virus
The recombinant CFTR adenoviras was constracted from the plasmid pAd.CB-CFTR and a modified adenovims type 5 (Ad 5), dllOOl, in which the majority of the E3 region (map units 78.4-86) was deleted. afZ7001 was kindly provided by Dr. William Wold from St. Louis. A description of this viral genome as provided to us is presented below verbatum. dlTOOl is derived from rec700, an AdS-Ad2-AdS recombinant which has the AdS EcoRI-A (map unit 0-76), Ad2 EcoRI-D (mu 76-83), and AdS EcoRI-B (mu 83-100) fragments. dllOOl retains Ad2 sequences from map position 76 to 78.4, and it is deleted of sequences from 78.4 to about 86. In terms of the nucleotide numbering for the E3 transcription unit dllOOl retains Ad2 sequence from nt -236 to 362 (See Cladaras and Wold, 1985) . The deletion extends from nt 362 in the Ad2 sequence to nt 3382 in the AdS sequence (nt 2437 in the Ad2 sequence conesponds to nt 2482 in the AdS sequence). The total deletion is 2,975 bp. Because of this deletion there are no authentic E3 AUG's or polyA sites.
pAd.CB-CFTR was linearized by Nhel cleavage and cotransfected with the large fragment of Clal-cut dllOOl DNA into 293 cells (a human kidney cell line containing a functional Ela gene that provides a trans-acting Ela protein) to allow homologous recombination to occur, followed by replication and encapsidation of recombinant adenoviral DNA into infectious virions and formation of plaques. Individual plaques were isolated and amplified in 293 cells, viral DNA was isolated, and recombinant adenoviral plaques containing the human CFTR cDNA were identified by restriction cleavage and Southem blot analysis. One of the positive plaques was plaque-purified a second time, and designated Ad.CB-CFTR. This viras was propagated in 293 cells and recovered 36-40 hr after infection by 3 cycles of freeze thawing. All viral preparations were purified by CsCl density centrifugation and either followed by gel filtration to remove CsCl for immediate use or stored at -20°C by diluting 1:5 into a glycerol/BSA solution. Titers of viral stocks were determined by plaque assay using 293 cells.
IV.C. Sequence Analysis of Recombinant Virus
Ad.CB-CFTR viral DNA has been isolated from the purified viral preparation obtained after two rounds of plague purification. Selected areas of the viral genome will be subjected to sequence analysis by Lark Sequencing Technologies, Inc. Sequence determination will be performed in compliance with FDA/GLP procedures.
Two areas of the genome will be subjected to complete sequence analysis including 1) the 5' end ofthe genome spanning the 5' ITR, the entire minigene cassette including CMV enhancer, p-actin promoter, CPTR cDNA, and a portion of E2. Regions to be sequenced will be subcloned as overlapping restriction fragments into pBluescript II (Strategene) and pGemSZf (Promega). Nested deletion clones will be generated in both directions for each of the subclones using a modified exoIII Sl nuclease procedure. These deletion clones will be size selected to provide complete coverage of each strand and sequenced using the dideoxynucleotide termination procedure. Intemal sequencing primers will be synthesized and used to close gaps between contigs and to fill in any single-stranded regions. We are in the process of negotiating a contract with Lark. Completion of the project will take approximately three months.
IV.D. Production of Virus
A critical part of the safety aspects of this protocol relates to the quality control and quality assurance associated with recombinant viras production. It is critical to demonstrate that the recombinant vims can be reproducibly manufactured in a way that the final product is of sufficient therapeutic quality and free of replication competent vims or other adventitious agents.
Viras production is performed in a BL2-I-facility that is solely dedicated for purposes of recombinant adenovimses. Within this laboratory there is a 4 ft laminar flow hood and double stack incubator that is dedicated to the production of Ad.CB-CFTR. The detailed standard operating procedures for producing vims are described below as is the strategy for assuring quality of the final product.
IV.D.l Strategy and Standard Operating Procedures
A master cell bank (MCB) of 293 cells will be established that has been evaluated for performance, in terms of production of recombinant adenoviruses, and for the absence of other pathogenic contaminants. The MCB will be infected with our initial Ad.CB-CFTR vims to generate a lysate. Vims will be purified and cryopreserved in aliquots. The lysate and purified seed lot will be subjected to safety testing as described in section I V.D. 2.
The MCB will be plated and infected with the virus seed lot. Lysates will be harvested from the infected cells and evaluated for sterility and mycoplasma testing. Vims will be purified from the lysate, cryopreserved, and lots will be evaluated as described in section I V.D. 2.
Production of Ad.CB-CFTR
Thirty ISOmm plates of about 90% confluent 293 cells were infected with Ad.CB-CFTR in 10 ml of DMEM/1% pen-strep with m.o.i. of 10 for two hr., then 20 ml of DMEM/1S% FBS/1% pen-strep was added. 36-40 hr post-infection, cells were harvested, pelleted, and resuspended in 10 mM Tris-Cl, pH8 .LA viral lysate was generated by three cycles of freezethawing (ethanol-dry ice bath/37°C water bath). Cell debris was removed by centrifugation for 20 min at 3,000 rpm at 4°C, and washed once with 10 mM Tris-Cl, pH 8.1. Supematants were pooled and loaded onto 20 ml of CsCl gradient made up of each volumes of 1.45g/ml(density) and 1.20 g/ml CsCl in 10 mM Tris-Cl, pH 8.1. Following a two hr spin at 20,000 rpm at 4°C in a SW 28 rotor, the adenovims band was removed by puncturing the tube with a needle, diluted with an equal volumes of 10 mM Tris-Cl, pH 8.1, and loaded onto a new gradient (8ml). Following an ovemight spin at 20,000 rpm at 4°C in a SW41 rotor, the viral band was removed and either stored at -20°C by diluting 1:5 into a glycerol/BSA solution (10 mM Tris-Cl, pH8.1, lOOmM NaCI, 0.1%BSA, 50% glycerol) or purified by gel filtration through a Sephadex G50 column for immediate use. Viral yield was determined by ODjeo (Particles/ml = ODjfio x dilution x lO'^/ml). Generally, a total of 3 x 10'^ viral particles was achieved from 30 plates.
IV.D.2. Quality Assurance and Quality Control
A four-stage test program has been designed to assess the cell bank, product intermediate (cell lysate) and the purified product (vims). The 293 cells used to produce the adenovirus will be characterized prior to infection for possible microbial, adventitious viral and select specific human viral contaminants. Testing of the adenoviras preparation used to infect the cells will include assays for microbial contaminants and adventitious viras. After expansion ofthe infected cells, the cell lysate will be evaluated for microbial contaminants. Product testing of the purified product for endotoxin, microbial contaminants, extraneous toxins and infectious adenovirus completes the test battery. Each step will be carefully tested for the presence of wild type adenoviras. The majority of tests will be performed by Microbiological Associates Inc. (MAI), an independent laboratory that has provided contract research and safety assessment for the pharmaceutical industry. A contract has been established with MAI for this project. Characterization of the MCB should be completed in three months.
IV.D.2.a Characterization of Master
Cell Bank (MCB)
The following tests will be performed on aliquots of the Master Cell Bank. These tests are based on the FDA's "points to consider" for use of mammalian cell lines. The MCB will be discarded if any test scores positive. The purpose of this study is to detect EBV DNA that may be present in the test article as detennined by Southem hybridization using a labeled DNA probe. DNA is extracted from the test article cell pellet and blotted onto membranes. Blotted membranes are hybridized to a labeled EBV probe and detected by autoradiography. DNA from Namalwa cells are included as a positive control. This assay is designed to detect the presence of human adenovims in the test article. Indicator cell culmres are inoculated and observed periodically for CPE. A passage is performed for enhancement.
IV.D.2.b Characterization of Adenovirus Seed Lot
Each seed lot will be prepared, cryoperserved and aliquots evaluated according to the following criteria: Each preparation of cell lysate will be pooled and aliquots will be evaluated for mycoplasma and sterility (see above for descriptions) before virus is purified. Any lysate demonstrating contamination will be discarded.
IV.D.2.d Characterization of Purified Lots of Ad.CB-CFTR for Therapy
Aliquots of each lot will be subjected to the following tests before use:
• The final preparation of purified Ad.CB-CFTR vims will be evaluated for the presence and concentration of virions capable of conecting the CF defect. The total particle number will be determined by measurement of the absorbance at 260nm. An aliquot of the virus preparation will be diluted serially and used to infect both 293 cells and the cell line CFPAC which was derived from a pancreatic adenocarcinoma of a patient with cystic fibrosis. The infected 293 cells will be evaluated for El transcomplementing viras using the previously described plaque forming assay. The infected CFPAC cells will be evaluated for CFTR protein expression by immunocytochemistry and conection of cAMP mediated chloride transport using SPQ assay. Descriptions of these assays are provided in section II.B.3. Several experiments will be performed to evaluate the viras preparations for contamination with wild type adenovirases. The presence of wild type adenovirases in the 293 cell line will be evaluated by M.A., Inc. using a standard assay in which a variety of indicator cell lines are exposed to 293 supernatants, passaged, and inspected for cytopathic effects. Detection and quantitation of low level wild type adenoviras in high titer preparations of the recombinant Ad.CB-CFTR viras is confounded by the observation that El deleted viruses will cause cytopathic effects (CPE) in non El expressing cells. such as HELA cells infected at high MOI's. Mechanism(s) for this relate to the direct toxic effect of high concentrations of viral proteins such as fiber and the possibility of low level viral replication of El deleted viras at high MOI. We find it necessary to dilute the concentrated stock at least 100 to 1000 fold to avoid CPE in most indicator cell lines. Two types of assays will be performed. A typical vims preparation contains 5 x 10'^ particles/ml based on OD at 260 nm and -10" functional virions/ml based on pfu or assays that measure CFTR protein expression (immunocytochemistry or SPQ functional analyses). The first assay is based on the ability of wild type Ad (but not EI deleted Ad) to replicate in nonEl expressing cell lines. An aliquot of each preparation representing 5% of the total will be diluted and exposed to a variety of indicator cell lines. The cells are passaged for 2 weeks to allow spread of wild type vims and subsequently examined for CPE. Specifically, for each ml of stock, 5 pl is removed, diluted and exposed to 10 x IS cm plates of confluent indicator cells. Preliminary results with purified preps of recombinant viruses have failed to demonstrate CPE under these conditions. The sensitivity of the assay is cunentiy being defined in reconstitution experiments.
Another assay has been developed to detect and quantify wild type AdS in the stocks of recombinant viras. The potential sources of wild type AdS are contamination from the initial transfection or recombination with AdS sequences originally transfected into the 293 cells. The assay is based on PCR detection of El sequences in DNA isolated from the stock of recombinant viras. An agarose gel of PCR products were mn in which 125 ng of total cellular DNA was supplemented with varying amounts of wild type Ad viral DNA(from 100,000 to 0.1 copies of AdS per reaction). Amplification for 35 cycles afforded a sensitivity equal to 100 viral molecules/reaction. However, when the initial reaction products were used as a template for another 35 cycles of amplification using nested primers, the sensitivity was improved to 1 viral molecule/ reaction. DNA will be isolated from five percent of each viral stock and subjected to the PCR analysis. Five percent of a 2 ml viral stock should yield 2-20 mg of DNA which can be analyzed in 4 to 40 reaction tubes.
V. Overall Assessment of Risks versus Benefits
V.A Risks to Human Subjects V.A.I Blood Draws a) Localized hematoma at the puncture site-appropriate pressure will be applied to the puncture site to prevent this common complication; Vaso-vagal faint-^patients will be asked to report any symptoms of lightheadedness or circumoral tingling which may precede a vaso-vagal episode; those individuals experiencing such symptoms will be kept in a recumbent position until this temporary reaction abates, b) If the above precautions are taken, the potential risk to blood donors is negligible. V.A.2 Bronchoscopy a) Bronchoalveolar lavage. Review of the literature indicates that bronchoscopy is a generally accepted investigational procedure in protocols involving patients with cystic fibrosis. We have located 9 published studies from 6 independent research groups in which investigational bronchoscopy was used in a total of 105 patients. Only one of the studies included information regarding complications of the procedure. The study of Wood et al. (1975) states, "Adverse effects of the procedure were limited to minor complications to be expected from transnasal fiberoptic bronchoscopy: Very mild epistaxis in one patient and hoarseness and pharyngitis for 2 days in another." Repeated bronchoscopies were performed in one study and no adverse effects were reported. An informal survey ofthe experience at two medical centers where cystic fibrosis research bronchoscopies have been performed (as many as 250) reveals three adverse effects: 1) coughing during the procedure, 2) fever lasting less than 24 hours in approximately 25-33% of subjects, and 3) fever with new pulmonary infiltrates in 1-3% ofthe subjects. We will address these potential problems by 1) using parenteral sedation and airway anesthesia, 2) administering acetaminophen 500 mg every 6 hours for 24 hours, and 3) prior treatment of subjects with intensified therapy to minimize airway inflammation prior to the procedure. b) Reaction to mediations: Very rare hypersensitivity reactions can occur to the sedative, anticholinergic, and topical anesthetic agents. Appropriate emergency equipment and medications will be immediately available for use in the unlikely event of such a reaction occuning. c) Anxiety: Anxiety provoked by anticipation of the bronchoscopic procedure will be lessened by providing the patient with a detailed description of the procedure and repeated opportunities to receive answers to any questions. Premedication with intravenous or intramuscular meperidine and intravenous midazolam will be used in doses to induce mild sedation. The subjects will be maintained so that they can be immediately aroused by verbal stimuli and can follow simple instractions. d) Vaso-vagal reactions: Glycopynolate will be administered intravenously immediately before bronchoscopy for its anti-cholinergic effects. e) Coughing: Minor discomfort from coughing occurs frequently during bronchoscopy. Premediation with meperidine and topical lidocaine will be used to diminish coughing. f) Pneumothorax: Pneumothorax is a very rare complication of flexible bronchoscopy when the procedure does not include transbronchial biopsies and is performed by experienced personnel. The bronchial bmshing procedure presents a very small risk of pneumothorax, estimated to be under 1 in 500-1000. This is particularly tme for the cunent study because the brash will be advanced only several centimeters into the segmental bronchus and not advanced into the distal bronchial tree. If abnormal resistance is met while advancing the brash, it will be retracted and redirected into another subsegmental orifice. g) Intrabronchial hemonhage: Minor superficial mucosal trauma can be induced when the bronchoscope mbs against the walls ofthe bronchi. An experienced bronchoscopist can minimize this by avoiding maneuvers that induce trauma and by insuring that the bronchoscope is well lubricated. Bronchial bmshing can induce bleeding because it abrades the superficial mucosa. Chronic bronchitis as occurs in cystic fibrosis may theoretically increase the risk of bleeding. The chances of severe bleeding will be minimized by insuring that the subjects have normal clotting parameters (protime, partial thromboplastin time, platelet count) and by excluding patients who have had major hemoptysis within the previous year. The consequence of intrabronchial bleeding will be minimized by insuring that the bronchoscopic is gently wedged into the subsegmental bronchus before bmshing is performed. In this position, the bronchoscope can tamponade any bleeding and provide access for administration of vasoconstrictor dmgs such as epinephrine. Serious bleeding resulting in the need for transfusion, acute respiratory decompensation, or fatality have been exceedingly rare. It has occuned almost exclusively in patients undergoing transbronchial biopsies (not being performed in this study) who also have underlying coagulopathies. At the University of Michigan between 1988 and 1990, only 4 of 773 bronchoscopies resulted in bleeding which was serious enough to require hospital admission. In no instances was transfusion required nor did respiratory decompensation occur. All bronchoscopies will be performed in a setting in which equipment is immediately available for intubation and assisted ventilation with supplemental oxygen. Intravenous access will be maintained throughout the procedure to provide a route for emergency administration of medications and fluids.
h) Post-bronchoscopy fever and pneumonia: Fever can occur within 12 hours of bronchoalveolar lavage, the cause of which is uncertain. Although its incidence is unknown, it probably occurs more frequentiy in patients with cystic fibrosis than in normal volunteers. An estimate of the frequency of post-bronchoscopy fever is 25-33% and of transient post-lavage infiltrates is 5%. There appears to be no serious sequela from these occunences.
V.A.3 Infusion of Recombinant Adenoviruses
Toxicity due to the adenoviras can be caused by several mechansims.
V.A.3.a Ectopic or overexpression of CFTR
We have performed a series of studies in animals to address these issues. The most compelling experiments involved the generation of transgenic mice that had been programmed to express high levels of human CPTR in the airway. One set of animals expressed CPTR from a promoter of the SPC gene that is very active in the distal airway including the alveolar cells and the distal bronchiolar cells. Another set of animals expressed CFTR from a promoter of the CCIO gene that is very active in most of the cells of the proximal airway. All of the transgenic lines expressed high levels of human CPTR protein (which is active in mouse cells) in the appropriate cells and none of them demonstrated pathology or clinical abnormalities. This suggests that expression of recombinant CPTR in the wrong cell or unregulated, overexpression in the conect cell will not be deleterious.
V.A.3.b Replication of the virus and expression of viral proteins
The viras has been engineered in a way that the region responsible for activating its transcriptional units, called El, has been deleted. In principal, therefore, the recombinant genome should not replicate or express viral proteins in the recipient cell. In practice, certain cell types under special conditions can transactivate the viral genes using endogenous cellular factors.
We have established a model of the CF airway that is based on the growth of human airway xenografts in nu/nu mice to better address these important issues in a relevant biological setting. This model was used to evaluate the possibility of viral protein expression and replication ofthe El deleted CPTR vims in the context of a human CF epithelium. These studies failed to detect viral protein expression or ongoing replication of the vims in human xenografts that were stably expressing the recombinant gene. Any replication and spread of the vims in this model would rapidly disseminate throughout the xenograft because it could not be contained by the immune system, which is absent in these nu/nu mice. We believe therefore that this is an extremely stringent test for viral protein expression and replication. The MOI we have selected to use in vivo in this study is estimated to be far below that required to cause cytopathic effects in vitro based on transactivation of the El deleted genome by cellular factors. The xenograft experiments have now been performed with cells derived from both cystic fibrosis and non cystic fibrosis patients with similar results, arguing against increased vimlence of the vims in the relevant biological setting of a deficiency of CFTR. The results of the non-human primate studies indicate that Ad.CBCFTR has the potential to induce pulmonary inflammation. The mechanism is likely to be an immune reaction to viral antigens. It is difficult to predict if similar inflammation will occur in humans. There are likely to be significant differences in the response to Ad.CBCFTR by humans compared to study animals. The adenovims from which Ad.CBCFTR was constracted is a human adenoviras and does not show the same cellular tropism and ability to replicate in the animal models. Furthermore, the human subjects will all have been previously exposed to type 5 adenovims as indicated by the presence of antibodies to it. As a phase I study, the primary purpose of this protocol is to assess the safety of gene transfer using an El-deleted adenovims. By using a shallow dose escalation protocol and sensitive measures of pulmonary inflammation, i.e. high resolution computerized tomography, minor amounts of pulmonary inflammation should be detectable.
It is important to consider the consequences of the unexpected dissemination of the recombinant viras or a replication competent derivative. Previous experience with adenovimses in humans suggests that they are relatively benign. Adenovimses are endemic in the population causing a variety of self-limited infections. Infection with AdS causes mild respiratory infections characterized by coryza, pharyngitis, fever, malaise, and tonsillitis. The relative safety of adenovirases was evaluated in a series of experiments, performed in the late 1960s and early 1970's, in which volunteers were exposed via the respiratory tract to wild types forms of adenovimses including the serotype used in this study (AdS). For example, in a study of Couch et al. (1973) normal adult volunteers were immunized to AdS capsid antigens and subsequentiy exposed to an inoculum of live AdS into the respiratory tract. Ten of 19 individuals who received a placebo immunization and subsequently live AdS had a self limited febrile illness characterized by fever and moderate pharyngitis. No significant untoward effects were noted.
An additional consideration relates to the malignant potential of these gene transfer reagents. In contrast to retrovirases which integrate into the genome, adenoviruses are maintained in the genome as extrachromosomal elements which theoretically cannot cause a secondary malignancy due to insertional mutagenesis. In support of this is the fact that no human malignancy has been directiy linked to adenovirases.
Psychological and social implications. It is likely that the initiation of these experiments will be associated with tremendous attention by the media. We will follow a strict code of confidentiality as mandated by the RAC and inform the patients of this potential problem.
V.B. Risks to Others
The only potential risk to others is the possibility that the recombinant viras could be transmitted to another individual, take up residence, and cause disease. We believe this is highly unlikely for a variety of reasons.
One very important aspect of this scenario relates to the likelihood that transmission of Ad.CB-CFTR will cause disease. We obviously do not think this is likely based on the fact that we are proposing to use it therapeutically. Toxicity could be due to one of two mechanisms: expression of CPTR or pathology due to the inherent properties of AdS. As we argued above, ectopic or unregulated overexpression of CPTR does not appear to be toxic. Furthermore, pathology of the recombinant due to its properties as an infectious viras is unlikely because all patients will have had previous immunity to the vims and the recombinant should have a tremendous growth disadvantage due to the deletion of El.
Another possibility is that the Ad.CB-CFTR will undergo a recombination with homologous wild type Ad to form a more toxic stmcture. As demonstrated below the most likely recombination will be between the large stretch of homology 3' to the CPTR minigene. This will form two recombinants: one containing the CFTR minigene with E3 sequences (this exceeds the wild type genome size; our attempts to actually make this vims have failed because it cannot be packaged) and a wild-type hybrid genome missing E3 sequences (there is no reason to expect this to be more pathogenic than either parent).
The next consideration relates to the probability that the Ad.CB-CPTR vims can replicate, spread and be transmitted. We believe that this will be unlikely based on our xenograft experiments which failed to recover any recombinant vims from the lumen within 7-10 days after exposure to titers of viras which will exceed that administered to the patients by 100 to 1000-fold. In order to assure that this does not occur we will keep the patients in isolation for a period of 10 days following the treatment. The patient's nasal swabs and sputum will be evaluated for Ad.CB-CPTR sequences before discharge. If there is evidence of ongoing spread the patient will be asked to stay in the hospital for additional days. We think this will be extremely unlikely. The other possible situation that could lead to spread is if the patient becomes superinfected with a homologous wild type viras which mobilizes the recombinant genome. It is impossible for this to occur through the generation of a replication competent vims containing the minigene due to size limitations of packaging. The spread ofthe genome would have to occur by adenoviral functions provided in trans. We think this is highly unlikely and should not prevent the study. In order to address this potential concem we will work with the Ad CFT« Wild Type Ad E3 deletion Ad X 100 J Map Units referring physician to be particulariy cognizant of signs and symptoms characteristic of adenoviral infections and will continue to survey nasal swabs for Ad.CB-CFTR sequences using die PCR assay.
V.C Potential Benefits
This is a Phase I study so there will be no actual benefits to the patients involved in the experimental protocol. This study could have enormous benefit to the larger community of CF patients for a variety of reasons. Despite tremendous investment of resources by the pharmaceutical industry, management of the pulmonary complications of CF is inadequate; patients eventually succumb to these complications by the age of thirty. The information gained in this study will provide information that is critical to the eventual development of effective treatments of the lung disease of CF by gene therapy. We hope to evaluate the overall safety of this approach as well as to assess the feasibility of obtaining genetic reconstitution that is therapeutic and stable. We do not believe that this trial will actually be therapeutic to the patient because the therapy will be administered to such a small surface area ofthe airway. For this very reason, it is felt that the procedure will not compromise pulmonary function if deleterious to the segment. We consider this an extremely important study with respect to evaluating the potential use of recombinant adenovirases in the treatment of cystic fibrosis. We would consider this a successful experiment if we can answer the critical questions addressing the safety and efficacy of this approach to gene therapy in cystic fibrosis. Based on our extensive work in animal models, we believe there is a reasonable chance that the study will show recombinant adenovirases are capable of safely transferring recombinant CFTR genes to the cystic fibrosis airway and that the genes function for a prolonged period of time.
An important banier to gene transfer into the surface epithelium of the airway is that the cells are relatively quiescent with approximately 0.1% of the cells going through the cell cycle at any one time. For this reason, approaches to gene therapy which depend on integration of the transgene into the recipient cell's chromosome, such as recombinant retrovirases, will not be effective. Recombinant adenovimses have the capability of transducing genes into nondividing cells and maintaining the transgene as an extrachromosomal element. We have used the human xenograft system to evaluate the stability of adenoviral mediated recombinant gene expression. We have found that recombinant adenovimses are capable of efficiently transfening genes into nondividing fully differentiated cells of the surface epithelium and that the recombinant gene expression is stable for the longevity of the grafts which is approximately 4 weeks. Furthermore this occurs in the absence of viral protein expression or detectable viral replication. Presuming the viral genome is stable in the cell, the persistence of recombinant gene expression becomes dependent on the lifespan of the cell. As described above the cells of the surface epithelium have a relatively long life span and xenograft experiments have demonstrated gene transfer into all cell types that line the lumen of the airway.
